Sep 27, 2021 / 01:20PM GMT
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research
Hi, everybody. It's Alethia Young here. I cover large cap, small mid cap biotech at Cantor. Obviously, this company needs no introduction, but Regeneron. We're actually going to be having a very specific conversation with Regeneron today around their Regeneron Genetics Medicines. I'm very happy to have the RGC leader, Dr. Aris Baras. He's SVP, General Manager at Regeneron Genetic Center and, of course we don't -- Justin doesn't need an introduction, with Justin Holko, he is VP of IR at Regeneron.
So we are going to do a fireside chat and we'll just dive right in, so --
Justin Holko - Regeneron Pharmaceuticals, Inc. - VP of IR
Alethia, maybe before we jump in, if I could just give the quick forward-looking statement. And then I think Aris has a couple of points, he'd probably like to jump in with.
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Director of Equity Research
Regeneron Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers